IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Gregory et al.

Examiner: Dr. K. C. Carlson

Serial No:

08/087,132

Art Unit: 1814

Filed:

July 2, 1993

Docket: IG 4-9.2(FWC)

Title:

New Diagnostic and Treatment Methods Involving the

Cystic Fibrosis Transmembrane Regulator

The Honorable Commissioner of Patent and Trademarks Washington, DC 20231

-- CERTIFICATE OF FACSIMILE TRANSMISSION --

I hereby certify that this correspondence is being transmitted by facsimile to the Honorable Assistant Commissioner of Patents, c/o Examiner Karen Carlson, Ph.D., Group 1800, Art Unit 1814, Washington, DC 20231, at (703) 308,7401

Date: 4/2/99

Elizabeth Lassen

Dear Sir:

Transmitted herewith is an AMENDMENT in the above identified application.

The fee has been calculated as shown below:

R	ATME CARCOPARTY		KI KAPA	AND TRACTOR	PATELANCE:	FIQE Commission of the
TOTAL	22	MINUS	133	= 0	x 22	\$ 0
lkener	4	MINUS	13	= 0	× 78	\$ 0
	A SACIA				× 250	0
			C.Chr. S.C.			\$ 0

NO NEW MULTIPLE DEPENDENT CLAIMS ARE BEING ADDED

TOTAL \$ 0

- 2. The Commissioner is hereby authorized and requested to charge \$__0_____ for the presentation of extra claims under 37 C.F.R. 1.16 and all patent processing fees under 37 C.F.R. 1.17, along with any additional fees under 37 C.F.R. 1.16 and 1.17, which may be required, or credit any overpayment, associated with this communication to Deposit Account No. 07-1074. A duplicate of this document is enclosed for this purpose.
- 3. Since the number of independent claims and the number of total claims that are now pending herein are substantially less than the numbers thereof that have been previously paid for, no fee is due in connection with this supplementary submission. However, the Patent Office is authorized to charge any fee that it determines is necessary in order to secure the filing of this Supplementary Reply and all enclosures.

Respectfully submitted, GENZYME CORPORATI

Elizabeth Lassen

Reg. No. 31,845

Attorney for Applicants

Dated: April 2, 1996

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CE D

ACCOUNTABILITY

DEPOSIT ACTOUNT NO

COU

Applicants:

Gregory et. al.

Examiner:

Dr. K. C. Carlson

Serial No.:

08/087,132

Art Unit:

1812

Filed:

July 2, 1993

Docket:

IG4-9.2(FWC)

For:

NEW DIAGNOSTIC AND TREATMENT METHODS

INVOLVING THE CYSTIC FIBROSIS TRANSMEMBRAITE VALUE

REGULATOR

BOX AF,

Honorable Commissioner of Patents and Trademarks, Washington, DC 20231

Payment of Fee for Transitional After Final Practice under 37 CFR 1.129(a) and 37 CFR 1.17(r)

SIR:

Applicants hereby request withdrawl of the final rejection that be pending herein under 37 CFR 1.129(a) "Transitional After Final Practice." Pursuant to 37 CFR 1.17(r) the Patent Office is hereby authorized to charge the transitional fee of \$750.00 to Deposit Account 07- 1074.

No extension fee is due in connection with the Reply with Amendment submitted herewith since it is being filed within the three months of the mailing of the Final Action that is pending herein. However, should the Patent Office determine that any other fee is necessary for acceptance of this paper, or for the claims presented herein, then the Patent Office is authorized to charge such fee to Deposit Account 07- 1074.

A duplicate of this Paper is enclosed.

08/087,132 January 16, 1996 page 2

Dated: January 16, 1996

One Mountain Road Framingham, MA 01701- 9322 (508) 872-8400 x 2555 Respectfully submitted,

GENZYME CORPORATION

By:

Mark A. Hofer, Esquire Registration No. 30,068 Attorney for Applicants